2 results
Approved WMORecruiting
* To decrease mortality in MS-LCH by an early switch of patients with risk organ involvement, who do not respond to front-line therapy, to a more intensive treatment (Stratum III or Stratum IV).* To reduce reactivation rates and permanent…
Approved WMOPending
To compare the effect of ZIM and DOM in combination with chemotherapy relative to PEMBRO in combination with chemotherapy (Group A versus Group B) on:• Progression-free survival (PFS) according to RECIST v1.1 as assessed by blinded independent…